Seizure : the journal of the British Epilepsy Association
-
Multicenter Study
Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study.
Treatment of status epilepticus (SE) has not changed in the last few decades, benzodiazepines plus phenytoin or valproate being the most common treatment. Once this first and second line treatment has failed SE is considered refractory (RSE). This study aimed to assess the efficacy and tolerability of intravenous (iv) lacosamide (LCM) in RSE. ⋯ LCM might be a fast, effective and safe add-on treatment in RSE.